State Street’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-67,950
| Closed | -$429K | – | 4871 |
|
|
2022
Q4 | $429K | Hold |
67,950
| – | – | ﹤0.01% | 3823 |
|
|
2022
Q3 | $348K | Buy |
67,950
+14,800
| +28% | +$92.9K | ﹤0.01% | 3915 |
|
|
2022
Q2 | $333K | Hold |
53,150
| – | – | ﹤0.01% | 3990 |
|
|
2022
Q1 | $189K | Buy |
53,150
+7,180
| +16% | +$26.5K | ﹤0.01% | 4403 |
|
|
2021
Q4 | $231K | Hold |
45,970
| – | – | ﹤0.01% | 4284 |
|
|
2021
Q3 | $337K | Buy |
45,970
+20,900
| +83% | +$143K | ﹤0.01% | 4133 |
|
|
2021
Q2 | $215K | Buy |
+25,070
| New | +$214K | ﹤0.01% | 4195 |
|
|
2019
Q4 | – | Sell |
-3,280
| Closed | -$46K | – | 3837 |
|
|
2019
Q3 | $46K | Buy |
3,280
+100
| +3% | +$1.65K | ﹤0.01% | 3727 |
|
|
2019
Q2 | $47K | Sell |
3,180
-44,331
| -93% | -$1.19M | ﹤0.01% | 3727 |
|
|
2019
Q1 | $1.99M | Buy |
47,511
+1,028
| +2% | +$43.3K | ﹤0.01% | 3146 |
|
|
2018
Q4 | $1.93M | Buy |
46,483
+6,482
| +16% | +$291K | ﹤0.01% | 3132 |
|
|
2018
Q3 | $1.93M | Buy |
40,001
+2,943
| +8% | +$147K | ﹤0.01% | 3259 |
|
|
2018
Q2 | $1.76M | Buy |
+37,058
| New | +$2.06M | ﹤0.01% | 3311 |
|
State Street's FSTX Position: Q1 2023 in Review
State Street sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 67,950 shares — an estimated $429K sold.
State Street first reported a position in FSTX in Q2 2018 and held it in 13 quarters. The position peaked at $1.99M in Q1 2019. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.
- State Street reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- State Street sold 67,950 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $429K.
- State Street first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2018 and held it in 13 quarters.
- State Street's F-star Therapeutics, Inc. Common Stock position peaked at $1.99M in Q1 2019.
- 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.
Based on State Street's 13F filing for Q1 2023, filed 15 May 2023.